HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin.
about
Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumoniaClinical evaluation of cefotaxime for therapy of lower respiratory tract infections.HR 756--a new cephalosporin in the treatment of gonorrhoea caused by ordinary and penicillinase-producing strains of Neisseria gonorrhoeae.Susceptibility of Neisseria gonorrhoeae to cefotaxime and ceftizoxime.In vitro activities of cefotaxime and moxalactam (LY127935) against Haemophilus influenzaeCefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing.Pharmacology of cefotaxime and its desacetyl metabolite in renal and hepatic disease.Cefotaxime treatment of pelvic inflammatory disease.Clinical efficacy of cefotaxime in serious infections.Gram-positive superinfections following beta-lactam chemotherapy: the significance of the enterococcus.Antibacterial activity of a new parenteral cephalosporin--HR 756: comparison with cefamandole and ceforanide.Cefotaxime diffusion into cerebrospinal fluid of children with meningitis.In vitro studies on the antibacterial activities of YM-13115, a new broad-spectrum cephalosporin.Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.Clinical pharmacology of cefotaxime in pediatric patients.Susceptibility of gram-positive cocci to various antibiotics, including cefotaxime, moxalactam, and N-formimidoyl thienamycin.Superior activity of N-formimidoyl thienamycin against gentamicin-resistant Pseudomonas aeruginosa.Mechanism of action, antimicrobial activity, pharmacology, adverse effects, and clinical efficacy of cefotaxime.Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins.GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae.Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds.Hydrolysis of Cefotaxime by a beta-lactamase from Bacteroides fragilis.In vitro antimicrobial activity of cefotaxime, a new cephalosporin.Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels.The antimicrobial activity of cefotaxime: comparative multinational hospital isolate surveys covering 15 years.In vitro activity of LY127935.LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics.Influence of inoculum size on activity of cefoperazone, cefotaxime, moxalactam, piperacillin, and N-formimidoyl thienamycin (MK0787) against Pseudomonas aeruginosaEffects of cefotaxime on the serum protein binding of sulfisoxazole.Cefotaxime therapy of serious infections with multiresistant gram-negative bacilli.
P2860
Q30451309-F6402580-5A5C-485D-90C8-CAD4DD8D0666Q30451377-C6098F68-FB27-4E77-B50A-0F04A1CFBC44Q33657545-E86C937F-F591-4C46-BE0F-AC9897238EA8Q33658114-FEB7EB51-AE25-4211-BD2E-2A73E9B850D5Q33726013-6EAA4573-34D5-4CFC-850C-3CA7463DF2A2Q33731210-0B1012AC-CCDF-469E-8A66-23BCA5DD2D39Q35669229-F38A6642-69B8-46F1-B270-A1CC53948A7AQ35672905-1669B6DF-8320-43B4-8C7B-718D47A07BC1Q35673235-87F9B2F1-DDAC-43D6-BF4D-5DCF43024B91Q38591480-55E89EA9-66D7-4F6C-8874-2BD51B279337Q39681275-7890E012-7603-4D8E-A8FC-71656203A0FBQ39834149-C523E0C0-7B70-4566-BA30-A1A16B4E1547Q39849664-E340C8C9-1F7A-4825-9C9A-DFF9E29203E6Q39854724-EF420FD4-7313-4A4A-8A08-95C48C4C130CQ39855869-B18128E1-228C-4D64-A804-765BE1E7E7BCQ39855945-268F85B6-547A-41B2-967B-8D57D9344907Q39856082-C5D2A168-4513-45C6-951A-0327ADFCAEF7Q40134639-05778E86-BD1B-46CA-AF9D-9A2E1D9D1B8CQ40281304-442D0241-55AA-4F4B-A03A-773939911F81Q40282054-C73867FB-70BF-47BF-B370-AD477A15C761Q40282126-DD7D845F-24CA-42F7-8842-40567D3F7984Q40282273-2CB79AAA-91E0-417E-9691-FD1FBD2ECCAAQ40282339-185C25C0-0388-4C73-96A1-9E321E83E041Q40282760-DA542BA6-4E47-461A-A320-C87DB9604D89Q40584325-6D79D8F2-FE5E-4FF4-9AE2-A0B9B6D20F32Q40620946-BD876D45-7050-4B78-B378-79AA79B320E5Q40621000-5181D7EC-2DEC-4061-865F-2CEAE30495ACQ40621564-F56D5720-3AEC-41B9-99EF-64EA04939655Q43770298-DDE247F2-2CF5-4C2E-8B37-DA1EABC118DBQ54526223-476DA4E4-6276-473B-9FC8-6B266A59BE33
P2860
HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin.
description
1978 nî lūn-bûn
@nan
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
1978年论文
@zh
1978年论文
@zh-cn
name
HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin.
@en
type
label
HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin.
@en
prefLabel
HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin.
@en
P2093
P2860
P356
P1476
HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin.
@en
P2093
P2860
P304
P356
10.1128/AAC.14.6.807
P407
P577
1978-12-01T00:00:00Z